Previous 10 |
SAN DIEGO , June 4, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof , Ph.D., ...
SAN DIEGO , May 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participat...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
Immunic to Host MS R&D Day and Participate in Investor Conferences in April Immunic to Host MS R&D Day and Participate in Investor Conferences in April PR Newswire NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a b...
--News Direct-- Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month, highlighting the disease's impact, development, and the unmet medical n...
--News Direct-- Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application, marking a significant step in the company's intellectual property (IP) strategy. ...